

DAFTAR PUSTAKA

1. Mendling W. Vaginal microbiota. In *Microbiota of the human body*. Cham: Springer; 2016. p. 83-93.
2. Amabebe E, Anumba DO. The vaginal microenvironment: the physiologic role of Lactobacilli. *Frontiers in Medicine*. 2018;5(181).
3. Petrova MI, Lievens E, Malik S, Imholz N, Lebeer S. Lactobacillus species as biomarkers and agents that can promote various aspects of vaginal health. *Front Physiol*. 2015;6(81).
4. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. *American journal of obstetrics and gynecology*. 2013; 209(6): 505-523.
5. Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High global burden and costs of vaginosis bacterial: a systematic review and meta-analysis. *Sex Transm Dis*. 2019;46(5):304-11.
6. Joesoef M.R, Karundeng A, Runtupalit C, Moran J.S, Lewis J.S, Ryan C.A. (2001). High rate of bacterial vaginosis among women with intrauterine devices in Manado, Indonesia. *Contraception*. 2001; 64(3), 169-172.
7. Pujiastuti AT, Murtiastutik D. Studi retrospektif: Vaginosis bakterial. *Berkala Ilmu Kesehatan Kulit dan Kelamin*. 2016;26(2): 1-7.
8. Siahaan RE, Niode NJ, Pandaleke TA. Profil vaginosis bakterial di Poliklinik Kulit dan Kelamin RSUP Prof. Dr. RD Kandou Manado periode Januari 2011-Desember 2015. *e-CliniC*, 2016; 4(2).
9. Kovachev S. Defence factors of vaginal lactobacilli. *Critical reviews in microbiology*. 2018;44(1):31-9.
10. Amin M, Goodarzi H, Orang Z, Farsi S, Jorfi M. Isolation and Identification of Lactobacillus Species from the Vagina and Their Antimicrobial Properties, *African Journal of Microbiology Research*. 2011;5(20): 3300-04.
11. Hillier SL, Holmes KK. Normal vaginal flora. *Sexually transmitted diseases*. 2008;4:290-304.
12. Nami Y, Haghshenas B, Khosroushahi AY. Molecular Identification and Probiotic Potential Characterization of Lactic Acid Bacteria Isolated from Human Vaginal Microbiota. *Advanced pharmaceutical bulletin*. 2018;8(4):683-95.
13. Ceccarani C, Foschi C, Parolin C, D'Antuono A, Gaspari V, Consolandi C, et al. Diversity of vaginal microbiome and metabolome during genital infections. *Sci Rep* 9. 2019;14095.
14. Deng ZL, Gottschick C, Bhujju S, Masur C, Abels C, Wagner-Doebler I. Metatranscriptome analysis of the vaginal microbiota reveals potential mechanisms for protection against metronidazole in vaginosis bacterial. *Msphere*. 2018;3(3):e00262-18.
15. Sirichoat A, Buppasiri P, Engchanil C, Namwat W, Faksri K, Sankuntaw N, Pasomsub E, Chantratita W, Lulitanond V. Characterization of vaginal microbiota in Thai women. *PeerJ*. 2018;6:e5977.
16. Bayigga L, Kateete DP, Anderson DJ, Sekikubo M, Nakanjako D. Diversity of vaginal microbiota in sub-Saharan Africa and its effects on HIV transmission and prevention. *Am J Obstet Gynecol*. 2019;220(2):155-166.
17. Hay P. Vaginal discharge. Management of Infective and Non-infective genital Conditions. 2018;46(6):319-24.

18. Li C, Wang T, Li Y, Zhang T, Wang Q, He J, et al. Probiotics for the treatment of women with vaginosis bacterial: A systematic review and meta-analysis of randomized clinical trials. *Eur J Pharmacol*. 2019;864:172660.
19. Tan H, Fu Y, Yang C, Ma J. Effects of metronidazole combined probiotics over metronidazole alone for the treatment of vaginosis bacterial: a meta-analysis of randomized clinical trials. *Arch Gynecol Obstet*. 2017;295(6):1331-1339.
20. Wijgert, J. H, Verwijs, M. C. Lactobacilli- containing vaginal probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and recommendations for future trial designs. *BJOG: An International Journal of Obstetrics & Gynaecology*. 2020; 127(2), 287-299.
21. Debsky, Panel. Statement of the Polish Gynecological Society Expert Panel on the usage of inVag, prOVag and prOVag gel in obstetrics and gynecology. *Ginekologia polska*. 2012;83(3), 233-236.
22. Blekhman R, Goodrich JK, Huang K, Sun Q, Bukowski R, Bell JT, et al. Host genetic variation impacts microbiome composition across human body sites [Internet]. *Genome Biology* 16. 2015 [cited 19 April 2-21].
23. Green KA, Zarek SM, Catherino WH. Gynecologic health and disease in relation to the microbiome of the female reproductive tract. *Fertil Steril*. 2015;104(6):1351-7.
24. Diop K, Dufour JC, Levasseur A, Fenollar F. Exhaustive repertoire of human vaginal microbiota. *Human Microbiome Journal*. 2019;11(100051).
25. Mirmonsef P, Zariffard MR, Gilbert D, Makinde H, Landay AL, Spear GT. Short- chain fatty acids induce pro- inflammatory cytokine production alone and in combination with toll- like receptor ligands. *Am J Reprod Immunol*. 2012;67(5):391-400.
26. Petrova MI, van den Broek M, Balzarini J, Vanderleyden J, Lebeer S. Vaginal microbiota and its role in HIV transmission and infection. *FEMS microbiology reviews*. 2013;37(5):762-92.
27. Godha K, Tucker KM, Biehl C, Archer DF, Mirkin S. Human vaginal pH and microbiota: an update. *Gynecol Endocrinol*. 2018;34(6):451-455.
28. Miller EA, Beasley D, Anna. E, Dunn RR, et al. Lactobacilli dominance and vaginal pH: why is the human vaginal microbiome unique? *Front Microbiol*. 2016;7(1936).
29. Mirmonsef P, Modur S, Burgad D, et al. Exploratory comparison of vaginal glycogen and Lactobacillus levels in premenopausal and postmenopausal women. *Menopause*. 2015;22(7):702-9.
30. Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. *Maturitas*. 2016;91:42-50.
31. Lewis FM, Bernstein KT, Aral SO. Vaginal microbiome and its relationship to behavior, sexual health, and sexually transmitted diseases. *Obstet Gynecol Actions*. 2017;129(4):643-654.
32. Achilles SL, Austin MN, Meyn LA, Mhlanga F, Chirenje ZM, Hillier SL. Impact of contraceptive initiation on vaginal microbiota. *Am J Obstet Gynecol*. 2018;218(6):622-e1-10.
33. Achilles SL, Hillier SL. The complexity of contraceptives: understanding their impact on genital immune cells and vaginal microbiota. *AIDS*. 2013;27(01):S5-15.
34. Nelson TM, Borgogna JC, Michalek RD, Roberts DW, Rath JM, Glover ED, Ravel J, Shardell MD, Yeoman CJ, Brotman RM. Cigarette smoking is associated with an altered vaginal tract metabolomic profile. *Sci Reports* 8. 2018;8(1):852.
35. Aldunate M, Srbinovski D, Hearps AC, Latham CF, Ramsland PA, Gugasyan R, et al. Antimicrobial and immune modulatory effects of lactic acid and short chain fatty

- acids produced by vaginal microbiota associated with eubiosis and vaginosis bacterial. *Front Physiol.* 2015; 6: 164.
36. Greenbaum S, Greenbaum G, Moran-Gilad J, Weintraub A. Ecological dynamics of the vaginal microbiome in relation to health and disease. *Am J Obstet Gynecol.* 2019;220(4):324-335.
 37. Han C, Li H, Han L, Wang C, Yan Y, Qi W, et al. Aerobic vaginitis in late pregnancy and outcomes of pregnancy. *Eur J Clin Microbiol Infect Dis.* 2019;38(2):233-239.
 38. Russo R, Karadja E, De Seta F. Evidence-based mixture containing *Lactobacillus* strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. *Benef Microbes.* 2019;10(1):19-26.
 39. Javed A, Parvaiz F, Manzoor S. Bacterial vaginosis: An insight into the prevalence, alternative treatments regimen and it's associated resistance patterns. *Microb Pathog.* 2019;127:21-30.
 40. Coughlin G, Secor M. Bacterial vaginosis: update on evidence-based care. *Adv Nurse Pract.* 2010;18(1):41-4, 53.
 41. Jain PJ, Bristow CC, Pines HA, Harvey-Vera A, Rangel G, Staines H, et al. Factors in the HIV risk environment associated with bacterial vaginosis among HIV-negative female sex workers who inject drugs in the Mexico-United States border region. *BMC Public Health.* 2018;18(1): 1032.
 42. Eastment MC, McClelland RS. Vaginal microbiota and susceptibility to HIV. *AIDS.* 2018;32(6):687-98.
 43. Verstraelen H, Swidsinski A. The biofilm in bacterial vaginosis. *Current Opinion in Infectious Diseases.* 2019;32(1):38-42.
 44. Bohbot J, Darai E, Bretelle F, Brami G, Daniel C, Cardot JM. Efficacy and safety of vaginally administered lyophilized *Lactobacillus crispatus* IP 174178 in the prevention of bacterial vaginosis recurrence. *J. Gynecol. Obstet. Hum. Reprod.* 2018;47(4):177.
 45. Bradshaw CS, Vodstrcil LA, Hocking JS, Law M, Pirotta M, Garland SM, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. *Clinical Infectious Diseases.* 2013;56(6):777-86.
 46. Javed A, Parvaiz F, Manzoor S. Bacterial vaginosis: An insight into the prevalence, alternative treatments regimen and it's associated resistance patterns. *Microbial Pathogenesis.* 2019;127:21-30.
 47. Coudray M, Madhivanan P. Bacterial vaginosis—A brief synopsis of the literature. *Eur J of Obstet Gynecol Reprod Biol.* 2020;245:143-148.
 48. Ranjit E, Raghubanshi BR, Maskey S, Parajuli P. Prevalence of bacterial vaginosis and its association with risk factors among nonpregnant women: A hospital based study. *Int J Microbiol.* 2018; 2018: 8349601.
 49. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis—striving for long-term cure. *BMC Infect Dis.* 2015; 15:292.
 50. Sobel R, Sobel JD. Metronidazole for the treatment of vaginal infections. *Expert Opin Pharmacother.* 2015; 16(7):1109–15.
 51. Recine N, Palma E, Domenici L, Giorgini M, Imperiale L. Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case–control study using *Lactobacillus rhamnosus* BMX 54 as adjuvant treatment against bacterial vaginosis. *Archives of gynecology and obstetrics.* 2016; 293(1), 101-107.

52. Ranjit E, Raghubanshi B. R, Maskey S, Parajuli P. Prevalence of bacterial vaginosis and its association with risk factors among nonpregnant women: A hospital based study. *International journal of microbiology*. 2018; 21(1), 9-10.
53. Bhattarai S. Prevalence of common types of vaginitis (Bacterial vaginosis, Candidiasis, Trichomoniasis) and their correlation with urinary tract infection among women visiting [Dissertation, thesis] (Doctoral dissertation). 2012; 15 (2), 18-30.
54. Damen J.G, Suleiman S.Z, Vem S.T, Goltong J, Kahansim M. Microbiological diagnosis of bacterial vaginosis in pregnant women in a resource limited setting in north central Nigeria. 2014;45(3):135.
55. Ibrahim S. M, Bukar M, Galadima G.B, Audu B.M, Ibrahim H. A. Prevalence of bacterial vaginosis in pregnant women in Maiduguri, North-Eastern Nigeria. *Nigerian journal of clinical practice*. 2014;17(2), 154-158.
56. Wang A, Ran C, Wang Y, Zhang Z, Ding Q, et al. Use of probiotics in aquaculture of China—a review of the past decade. *Fish & shellfish immunology*. 2019; 86, 734-755.

